Log in or Sign up
to access My Account functionalities
My Account Area
Find similiar products:
Same active ingredient
By ATC code
Add to Favourites
Share via email
Report side effect
Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Back to top
Clindamycin 150mg/ml Solution for Injection or Infusion
ADVANZ PharmaSee contact details
Prescription only medicine
My Account Area
Log in or Sign up
to access My Account functionalities
Find similiar products:
Same active ingredient
By ATC code
Add to Favourites
Share via email
Healthcare Professionals (SmPC)HCP Med Info
This information is for use by healthcare professionals
Last updated on emc:20 Jan 2022
Undesirable EffectsPharmacological PropertiesInteractionsPosologyContraindicationsExcipients
Print SmPC information
1. Name of the medicinal product
Clindamycin 150mg/ml Solution for Injection or Infusion
2. Qualitative and quantitative composition
Each 1ml of solution contains clindamycin phosphate equivalent to 150mg clindamycin.
Each 2ml ampoule contains 300mg clindamycin
Each 4ml ampoule contains 600mg clindamycin
Excipients with known effect:
Sodium 6.57mg per ml (prior to dilution)
For the full list of excipients, see section 6.1.
3. Pharmaceutical form
Solution for Injection or Infusion
Clear, colourless, solution.
4. Clinical particulars
4.1 Therapeutic indications
Antibacterial. Serious infections caused by susceptible Gram-positive organisms, staphylococci (both penicillinase- and non-penicillinase-producing), streptococci (except Streptococcus faecalis) and pneumococci. It is also indicated for the treatment of severe infections caused by susceptible anaerobic pathogens such as Bacteroides spp, Fusobacterium spp, Propionibacterium spp, Peptostreptococcus spp. and microaerophilic streptococci. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Clindamycin does not penetrate the blood/brain barrier in therapeutically effective quantities.
4.2 Posology and method of administration
Parenteral (IM or IV administration) - 'see Method of administration' below.
Serious infections: 600mg-1.2g/day in two, three or four equal doses.
More severe infections: 1.2-2.7g/day in two, three or four equal doses.
Single I.M. injections of greater than 600mg are not recommended nor is administration of more than 1.2g in a single one-hour infusion.
For more serious infections, these doses may have to be increased. In life-threatening situations, doses as high as 4.8g daily have been given intravenously to adults.
Alternatively, the drug may be administered in the form of a single rapid infusion of the first dose followed by continuous IV infusion.
Treatment for infections caused by beta-haemolytic streptococci should be continued for at least 10 days to guard against subsequent rheumatic fever or glomerulonephritis.
Elderly: The half-life, volume of distribution and clearance, and extent of absorption after administration of clindamycin phosphate are not altered by increased age. Analysis of data from clinical studies has not revealed any age-related increase in toxicity. Dosage requirements in elderly patients should not be influenced, therefore, by age alone. See Precautions for other factors which should be taken into consideration.
Paediatric population (over 1 month of age):
Serious infections: 15-25mg/kg/day in three or four equal doses.
More severe infections: 25-40mg/kg/day in three or four equal doses. In severe infections it is recommended that children be given no less than 300mg/day regardless of body weight.
Method of administration
Parenteral (IM or IV administration).
Clindamycin 150mg/ml Solution for Injection and Infusion should be used undiluted for IM administration.
Clindamycin 150mg/ml Solution for Injection and Infusion must be diluted prior to I.V. administration and should be infused over at least 10-60 minutes.
Dilution for IV use and IV infusion rates
The concentration of clindamycin in diluent for infusion should not exceed 18mg per ml and INFUSION RATES SHOULD NOT EXCEED 30MG PER MINUTE. The usual infusion rates are as follows:
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Clindamycin 150mg/ml Solution for Injection and Infusion is contra-indicated in patients previously found to be sensitive to lincomycin
4.4 Special warnings and precautions for use
Severe hypersensitivity reactions, including severe skin reactions such as drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP) have been reported in patients receiving clindamycin therapy. If a hypersensitivity or severe skin reaction occurs, clindamycin should be discontinued and appropriate therapy should be initiated (see sections 4.3 and 4.8).
Clindamycin 150mg/ml Solution for Injection and Infusion should only be used in the treatment of serious infections. In considering the use of the product, the practitioner should bear in mind the type of infection and the potential hazard of the diarrhoea which may develop, since cases of colitis have been reported during, or even two or three weeks following, the administration of clindamycin.
Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of Clostridium difficile. This has been reported with use of nearly all antibacterial agents, including clindamycin. Clostridium difficile produces toxins A and B which contribute to the development of Clostridium difficile associated diarrhoea (CDAD) and is a primary cause of 'antibiotic-associated colitis'. The disease is likely to follow a more severe course in older patients or patients who are debilitated. Diagnosis is usually made by the recognition of the clinical symptoms, but can be substantiated by endoscopic demonstration of pseudomembranous colitis. Colitis is a disease, which has a clinical spectrum from mild, watery diarrhoea to severe, persistent diarrhoea, leucocytosis, fever, severe abdominal cramps, which may be associated with the passage of blood and mucus. If allowed to progress, it may produce peritonitis, shock and toxic megacolon. This may be fatal. The presence of the disease may be further confirmed by culture of the stool for C. difficile on selective media and assay of the stool specimen for the toxin(s) of C. difficile.
It is important to consider the diagnosis of CDAD in patients who present with diarrhoea subsequent to the administration of antibacterial agents. This may progress to colitis, including pseudomembranous colitis (see section 4.8), which may range from mild to fatal colitis. If antibiotic-associated diarrhoea or antibiotic-associated colitis is suspected or confirmed, ongoing treatment with antibacterial agents, including clindamycin, should be discontinued and adequate therapeutic measures should be initiated immediately. When 125 mg to 500 mg of vancomycin are administered orally four times a day for 7 - 10 days, there is a rapid observed disappearance of the toxin from faecal samples and a coincident clinical recovery from the diarrhoea. Drugs inhibiting peristalsis are contraindicated in this situation.
Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhoea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.
Caution should be used when prescribing Clindamycin 150mg/ml Solution for Injection and Infusion to individuals with a history of gastro-intestinal disease, especially colitis.
Since Clindamycin 150mg/ml Solution for Injection and Infusion does not diffuse adequately into cerebrospinal fluid, the drug should not be used in the treatment of meningitis.
If therapy is prolonged, liver and kidney function tests should be performed. Acute kidney injury, including acute renal failure, has been reported infrequently. In patients suffering from pre-existing renal dysfunction or taking concomitant nephrotoxic drugs, monitoring of renal function should be considered (see section 4.8). Such monitoring is also recommended in neonates and infants. Safety and appropriate dosage in infants less than one month old have not been established.
The use of Clindamycin 150mg/ml Solution for Injection and Infusion may result in the overgrowth of non-susceptible organisms particularly yeasts.
Prolonged administration of Clindamycin 150mg/ml Solution for Injection and Infusion, as with any anti-infective, may result in super-infection due to organisms resistant to clindamycin.
Care should be observed in the use of Clindamycin 150mg/ml Solution for Injection and Infusion in atopic individuals.
Clindamycin phosphate should not be injected intravenously undiluted as a bolus, but should be infused over at least 10-60 minutes as directed in section 4.2.
This medicine contains less than 1 mmol sodium (23 mg) per 2 ml ampoule, that is to say essentially 'sodium-free'.
This medicinal product contains 26 mg sodium per 4 ml ampoule, equivalent to 1.3% of the WHO recommended maximum daily intake of 2 g sodium for an adult.”
4.5 Interaction with other medicinal products and other forms of interaction
Clindamycin administered by injection has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. It should be used with caution, therefore, in patients receiving such agents.
Vitamin K antagonists
Increased coagulation tests (PT/INR) and/or bleeding have been reported in patients treated with clindamycin in combination with a vitamin K antagonist (e.g. warfarin, acenocoumarol and fluindione). Coagulation tests, therefore, should be frequently monitored in patients treated with vitamin K antagonists. \
Co-administration of clindamycin with inhibitors of CYP3A4 and CYP3A5
Clindamycin is metabolized predominantly by CYP3A4, and to a lesser extent by CYP3A5, to the major metabolite clindamycin sulfoxide and minor metabolite N desmethylclindamycin. Therefore inhibitors of CYP3A4 and CYP3A5 may reduce clindamycin clearance and inducers of these isoenzymes may increase clindamycin clearance. In the presence of strong CYP3A4 inducers such as rifampicin, monitor for loss of effectiveness.
In vitro studies indicate that clindamycin does not inhibit CYP1A2, CYP2C9, CYP2C19, CYP2E1 or CYP2D6 and only moderately inhibits CYP3A4. Therefore, clinically important interactions between clindamycin and co-administered drugs metabolized by these CYP enzymes are unlikely.
4.6 Fertility, pregnancy and lactation
There was evidence of maternal toxicity and embryofetal toxicity in animal studies (see section 5.3).
Clindamycin crosses the placenta in humans. After multiple doses, amniotic fluid concentrations were approximately 30% of maternal blood concentrations.
In clinical trials with pregnant women, the systemic administration of clindamycin during the second and third trimesters has not been associated with an increased frequency of congenital abnormalities. There are no adequate and well-controlled studies in pregnant women during the first trimester of pregnancy.
Clindamycin should be used in pregnancy only if clearly needed.
Orally and parenterally administered clindamycin has been reported to appear in human breast milk in ranges from 0.7 to 3.8 μg/ml. Because of the potential for serious adverse reactions in nursing infants, clindamycin should not be taken by nursing mothers
Fertility studies in rats treated orally with clindamycin revealed no effects on fertility or mating ability.
4.7 Effects on ability to drive and use machines
Clindamycin has no or negligible influence on the ability to drive and use machines.
4.8 Undesirable effects
The table below lists the adverse reactions identified through clinical trial experience and post-marketing surveillance by system organ class and frequency. The frequency of undesirable effects listed below is defined using the following convention:
Very common (≥1/10), Common (≥1/100 to <1/10), Uncommon (≥1/1,000 to <1/100), Rare (≥1/10,000 to <1/1,000), Very rare (<1/10,000), Not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
System organ class
Infections and infestations
vaginal infection *
Blood and lymphatic system disorders
agranulocytosis*, neutropenia*, thrombocytopenia*, leukopenia*, eosinophilia
Immune system disorders
anaphylactic shock*, anaphylactoid reactions*, anaphylactic reaction*, hypersensitivity*
Nervous system disorders
cardio- respiratory arrest†§
Oesophageal ulcers, oesophagitis, , vomiting, abdominal pain
Skin and subcutaneous tissue disorders
urticaria erythema multiforme, pruritus
toxic epidermal necrolysis (TEN)*, Stevens-Johnson syndrome (SJS)*, drug reaction with eosinophilia and systemic symptom (DRESS)*, acute generalised exanthematous pustulosis (AGEP)*, dermatitis exfoliative*, dermatitis bullous*, rash morbilliform*,
Renal and urinary disorders
Acute kidney injury#
General disorders and administration site conditions
pain†, injection site abscess†
injection site irritation†*
liver function test abnormal
* ADR identified post-marketing.
† ADRs apply only to injectable formulations.
# See section 4.4.
§ Rare instances have been reported following too rapid intravenous administration (see section 4.2)
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
In cases of overdosage no specific treatment is indicated.
The serum biological half-life of Clindamycin is 2.4 hours. Clindamycin cannot readily be removed from the blood by dialysis or peritoneal dialysis.
If an allergic adverse reaction occurs, therapy should be with the usual emergency treatments, including corticosteroids, adrenaline and antihistamines.
5. Pharmacological properties
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Lincosamides, ATC Code: J01 FF01
Mechanism of action
Clindamycin is a lincosamide antibiotic with a primarily bacteriostatic action against Gram-positive aerobes and a wide range of anaerobic bacteria. Lincosamides such as clindamycin bind to the 50S subunit of the bacterial ribosome similarly to macrolides such as erythromycin and inhibit the early stages of protein synthesis. The action of clindamycin is predominantly bacteriostatic although high concentrations may be slowly bactericidal against sensitive strains. Although clindamycin phosphate is inactive in vitro, rapid in vivo hydrolysis converts this compound to the antibacterially active clindamycin.
Resistance to clindamycin usually occurs via macrolide-lincosamide-streptogramin B (MLSB) type of resistance, which may be constitutive or inducible.
The minimum inhibitory concentrations (MIC) breakpoints are as follows:
Staphylococci: sensitive ≤ 0.25 resistant > 0.5
Streptococci ABCG and pneumoniae: sensitive ≤ 0.5 resistant > 0.5
Gram positive anaerobes: sensitive ≤ 4 resistant > 4
Gram negative anaerobes: sensitive ≤ 4 resistant > 4
Efficacy is related to the ratio of the area of the concentration-time curve of unbound antibiotic to the MIC for the pathogen (fAUC/MIC).
The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.
Staphylococcus aureus *
AnaerobesBacteriodes fragilis group
Prevotella formerly known as Bacteroides melaninogenicus
* Up to 50% of methicillin-susceptible S. aureus have been reported to be resistant to clindamycin in some areas. More than 90% of methicillin-resistant S.aureus (MRSA) are resistant to clindamycin and it should not be used while awaiting susceptibility test results if there is any suspicion of MRSA.
Most Gram-negative aerobic bacteria, including the Enterobacteriaceae, are resistant to clindamycin. Clindamycin demonstrates cross-resistance with lincomycin. When tested by in vitro methods, some staphylococcal strains originally resistant to erythromycin rapidly developed resistance to clindamycin. The mechanisms for resistance are the same as for erythromycin, namely methylation of the ribosomal binding site, chromosomal mutation of the ribosomal protein and in a few staphylococcal isolates enzymic inactivation by a plasmid-mediated adenyltransferase
5.2 Pharmacokinetic properties
General characteristics of active substance
Following parenteral administration, the biologically inactive clindamycin phosphate is hydrolysed to clindamycin. When the equivalent of 300mg of clindamycin is injected intramuscularly, a mean peak plasma concentration of 6 microgram/ml is achieved within three hours; 600mg gives a peak concentration of 9 microgram/ml. In children, peak concentration may be reached within one hour. When the same doses are infused intravenously, peak concentrations of 7 and 10 micrograms per ml respectively are achieved by the end of infusion.
Clindamycin is widely distributed in body fluids and tissues, including bone, but it does not reach the cerebrospinal fluid in significant concentrations. It diffuses across the placenta into the foetal circulation and appears in breast milk. High concentrations occur in bile. It accumulates in leucocytes and macrophages. Over 90% of clindamycin in the circulation is bound to plasma proteins. In vitro studies in human liver and intestinal microsomes indicated that clindamycin is predominantly oxidized by CYP3A4, with minor contribution from CYP3A5, to form clindamycin sulfoxide and a minor metabolite, N- desmethylclindamycin. The half-life is 2 to 3 hours, although this may be prolonged in pre-term neonates and patients with severe renal impairment.
Clindamycin undergoes metabolism, to the active N-demethyl and sulphoxide metabolites and also some inactive metabolites.
About 10% of the drug is excreted in the urine as active drug or metabolites and about 4% in the faeces; the remainder is excreted as inactive metabolites. Excretion is slow and takes place over several days. It is not effectively removed from the blood by dialysis.
Characteristics in patients
No special characteristics. See section 4.4 "Special warnings and special precautions for use" for further information.
5.3 Preclinical safety data
Impairment of fertility
Fertility studies in rats treated orally with up to 300 mg/kg/day (2-fold the human exposure based on mg/m2) revealed no effects on fertility or mating ability.
In oral embryo-fetal development studies in rats and subcutaneous embryo-fetal development studies in rats and rabbits, embryo-fetal toxicity was observed at doses that produced maternal toxicity. In rats, maternal death occurred with an exposure ratio of approximately 1 relative to patient exposure. In rabbits, maternal toxicity, including abortions, occurred at exposure ratio of approximately 0.1. Embryo-fetal toxicity, including post-implantation loss and decreased viability, occurred in rabbits at an exposure ratio of 0.2.
Long term studies in animals have not been performed with clindamycin to evaluate carcinogenic potential.
Genotoxicity tests performed included a rat micronucleus test and an Ames test.
Both tests were negative.
6. Pharmaceutical particulars
6.1 List of excipients
Sodium hydroxide (for pH adjustment)
Water for injections
Solutions of clindamycin salts have a low pH and incompatibilities may reasonably be expected with alkaline preparations or drugs unstable at low pH. Incompatibility has been reported with: ampicillin sodium, aminophylline, barbiturates, calcium gluconate, ceftriaxone sodium, ciprofloxacin, diphenylhydantoin, idarubicin hydrochloride, magnesium sulphate, phenytoin sodium and ranitidine hydrochloride. This medicinal product must not be mixed with other medicinal products except those mentioned in sections 6.6.
6.3 Shelf life
Unopened: 2 years
After dilution: 24 hours
Chemical and physical in-use stability has been demonstrated for 24 hours at 25°C. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally be no longer than 24 hours at 2 to 8°C, unless reconstitution/dilution (etc) has taken place in controlled and validated aseptic conditions.
6.4 Special precautions for storage
Do not store above 25°C. Keep ampoules in the outer carton. Do not refrigerate or freeze.
Please refer to Sections 6.3 and 6.6 for storage after dilution.
6.5 Nature and contents of container
Type 1 flint glass ampoule containing 2ml or 4ml sterile, aqueous solution, packed in cardboard carton, together with a leaflet. 1 or 5 ampoules in each pack.
Not all pack sizes may be marketed.
6.6 Special precautions for disposal and other handling
Any unused product or waste material should be disposed of in accordance with local requirements.
Solution for injection is for single use only. Any unused product should be discarded.
Infusion: Clindamycin 150mg/ml Solution for Injection and Infusion has been shown to be physically and chemically compatible for at least 24 hours in dextrose 5% water and sodium chloride injection solutions containing the following antibiotics in usually administered concentrations: Amikacin sulphate, aztreonam, cefotaxime sodium, , ceftazidime sodium, gentamicin sulphate, , piperacillin and tobramycin. The compatibility and duration of stability of drug admixtures will vary depending upon concentration and other conditions. The compatibility and duration of stability of drug admixtures will vary depending upon concentration and other conditions. The reconstitution/dilution should be made under aseptic conditions. The solution should be inspected visually for particulate matter and discoloration prior to administration. The solution should only be used if the solution is clear and free from particles.
7. Marketing authorisation holder
Focus Pharmaceuticals Ltd
85 King William Street,
London EC4N 7BL,
8. Marketing authorisation number(s)
9. Date of first authorisation/renewal of the authorisation
10. Date of revision of the text
Capital House, 1st Floor, 85 King William Street, London, EC4N 7BL, UK
+44 (0)208 588 9131
Medical Information Direct Line
+44 (0)208 588 9131
Medical Information e-mail
Customer Care direct line
+44 (0)208 588 9273
Clindamycin 150mg/ml solution for injection or infusion (called Clindamycin Injection in the rest of this leaflet). belongs to a group of medicines called antibiotics. Antibiotics are used to treat infections. Clindamycin injection is used to kill certain serious bacterial infections.What is clindamycin summary? ›
Clindamycin is a lincosamide antibiotic with a primarily bacteriostatic action against Gram-positive aerobes, and a wide range of anaerobic bacteria. Most Gram-negative aerobic bacteria, including the Enterobacteriaceae, are resistant to clindamycin.What is a clindamycin injection 150 mg used for? ›
Clindamycin injection is used to treat certain types of bacterial infections, including infections of the lungs, skin, blood, bones, joints, female reproductive organs, and internal organs. Clindamycin is in a class of medications called lincomycin antibiotics. It works by slowing or stopping the growth of bacteria.What are the guidelines for clindamycin? ›
Adults—150 to 300 milligrams (mg) every 6 hours. For more severe infections, 300 to 450 mg every 6 hours. Children weighing 10 kilograms (kg) or more—Dose is based on body weight and must be determined by your doctor.How long does clindamycin infusion take? ›
Clindamycin 150mg/ml Solution for Injection and Infusion must be diluted prior to I.V. administration and should be infused over at least 10-60 minutes.How long does it take clindamycin to work for bacterial infection? ›
How soon will it start working? Once you start taking clindamycin, you'll likely notice an improvement in your symptoms after a day or two. If your symptoms aren't improving at all or seem to be getting worse after taking clindamycin for a few days, follow up with your healthcare provider.Is clindamycin a very strong antibiotic? ›
Is Clindamycin a powerful antibiotic? Yes, Clindamycin is a strong broad-based antibiotic doctors prescribe to treat severe infections, including the fatal MRSA infection. It has a positive effect on various bacterial infections, including those which survive without air.Why did my doctor prescribe clindamycin? ›
Why is this medication prescribed? Clindamycin is used to treat certain types of bacterial infections, including infections of the lungs, skin, blood, female reproductive organs, and internal organs. Clindamycin is in a class of medications called lincomycin antibiotics.Why do I feel weird after taking clindamycin? ›
This medication can cause gastrointestinal side effects, such as nausea, vomiting, or diarrhea, which can be severe. If you already have a gastrointestinal disease, taking clindamycin may worsen your condition. In this case, your doctor may recommend more frequent monitoring or a different treatment option for you.Is 150 mg of clindamycin strong? ›
The dosages for clindamycin capsules for adults are: for serious infections, 150–300 mg every 6 hours. for more severe infections, 300–450 mg every 6 hours.
Serious skin reactions can occur with this medicine. Check with your doctor right away if you have blistering, peeling, or loose skin, red skin lesions, severe acne or skin rash, sores or ulcers on the skin, or fever or chills while you or your child are using this medicine.What bacteria does clindamycin treat? ›
Clindamycin is a lincosamide antibiotic that has been approved by the US Food and Drug Administration for the treatment of anaerobic, streptococcal, and staphylococcal infections.What are common side effects of clindamycin? ›
- Abdominal or stomach cramps, pain, and bloating (severe)
- diarrhea (watery and severe), which may also be bloody.
- increased thirst.
- nausea or vomiting.
- unusual tiredness or weakness.
- weight loss (unusual)—these side effects may also occur up to several weeks after you stop using this medicine.
The following reactions have been reported with the use of clindamycin. Gastrointestinal: Abdominal pain, pseudomembranous colitis, esophagitis, nausea, vomiting, and diarrhea (see BOXED WARNING). The onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment (see WARNINGS).What Cannot be used with clindamycin? ›
Medications that worsen clindamycin side effects
These medications are notorious for getting in the way of these enzymes: Heart medications like amiodarone (Pacerone) and verapamil. Heartburn medications like cimetidine (Tagamet HB) Antibiotics like clarithromycin.
Precautions. If your acne does not improve within about 6 weeks, or if it becomes worse, check with your health care professional. However, treatment of acne may take up to 8 to 12 weeks before full improvement is seen.How long is clindamycin IV good for? ›
6, 9 and 12 mg/mL (equivalent to clindamycin base) in dextrose injection 5%, sodium chloride injection 0.9%, or Lactated Ringers Injection in Mini-Bag containers demonstrated physical and chemical stability for at least eight weeks at -10°C.Why do you have to wait 10 minutes after taking clindamycin? ›
To prevent irritation in the esophagus, try to remain upright for at least 10 to 30 minutes after taking clindamycin, and swallow the pill with a full glass of water. Many other common medications may cause the same complications, including: Other antibiotics, such as doxycycline, tetracycline.How long do you have to lie down after taking clindamycin? ›
Do not lie down for at least 10 minutes after taking this medication. The dosage is based on your medical condition and response to treatment. In children, the dose is also based on weight.Is clindamycin better in the morning or night? ›
The time of day you use clindamycin does not matter as long as you're consistent. If you apply your medication in the morning, do so every morning. Ideally, it should be done at the same time each day. If you're using your medication twice a day, apply your evening medication 12 hours after your morning medication.
Amoxicillin has an average rating of 6.2 out of 10 from a total of 357 ratings on Drugs.com. 52% of reviewers reported a positive effect, while 32% reported a negative effect. Clindamycin has an average rating of 5.7 out of 10 from a total of 789 ratings on Drugs.com.Why is clindamycin not used anymore? ›
Clindamycin no longer recommended
This is because clindamycin is known to cause more severe adverse reactions such as C. diff. In fact, one dose of clindamycin has an equivalent risk of C. diff compared with a prolonged course.
Sir Alexander Fleming, Ernst Boris Chain, and Sir Howard Walter Florey shared the 1945 Nobel Prize in Physiology or Medicine for the discovery of penicillin and its ability to treat a variety of infectious ailments. Vancomycin 3.0 is one of the most potent antibiotics ever created.Is clindamycin as good as penicillin? ›
No, clindamycin is not a penicillin antibiotic. Instead, it belongs to a class of medications known as lincomycin antibiotics, or lincosamides. It makes it hard for bacteria to reproduce by blocking it from making certain proteins.Is clindamycin a good antibiotic for COVID? ›
Seventhly, common orthopaedic antibiotics including penicillin and clindamycin are safe to continue for COVID-19 patients. However, for COVID-19 patients, the antibiotics can potentially be switched to macrolides and tetracyclines if the organisms are sensitive.Can clindamycin treat a sinus infection? ›
Clindamycin is an antibiotic used to fight against a bacterial infection in the body. Clindamycin is used to treat a wide variety of bacterial infections, including: Acne, acute sinus infections, skin infections, some vaginal infections and more.Why does my chest hurt after taking clindamycin? ›
Certain medications can irritate and erode the lining of the esophagus, leading to esophagitis or ulcers. This can cause heartburn, chest pain, and difficulty swallowing. Many of these medications — like doxycycline, clindamycin, and ibuprofen — have alternatives that may be gentler on the stomach.Can clindamycin cause mental problems? ›
In support of this view is the fact that in a rodent study, both clindamycin and amoxicillin were found to increase depressive-like behaviours .Can clindamycin make you lose weight? ›
SIDE EFFECTS: This medication may cause stomach upset, diarrhea, nausea, vomiting, heartburn, cramps, bloating or weight loss, which should disappear in a few days as your body adjusts to the medication. If these symptoms persist or become severe, inform your prescriber.Can a UTI be treated with clindamycin? ›
Clindamycin is a lincosamide antibiotic. It is often used to treat certain bacterial infections, including skin and dental infections. In rare cases, it may be used to treat UTIs in those with allergies to more standard UTI treatment. Clindamycin is available as a generic and under the brand name Cleocin.
Although you can take clindamycin with food or on an empty stomach, it may cause less stomach upset if taken with food. Many things can affect the dose of a medication that a person needs, such as body weight, other medical conditions, and other medications.Is it okay to drink milk while taking clindamycin? ›
Similarly, it's recommended that antibiotics are not taken with fruit juices or dairy products, as they can affect the body's ability to absorb the medication. Instead, it is recommended that the drug is taken with water only.Does clindamycin damage kidneys? ›
Clindamycin is potentially nephrotoxic. Acute kidney injury including acute renal failure has been reported.Is clindamycin hard on the liver? ›
Clindamycin has been linked to rare instances of acute liver injury.What bacteria does clindamycin not cover? ›
Therefore, clindamycin is used primarily to treat anaerobic infections, including acute dental abscess, acute sinusitis and aspiration pneumonitis. Clindamycin is not active against aerobic and facultatively anaerobic Gram-negative bacilli.Does clindamycin harm gut bacteria? ›
Clindamycin, a br-oad-spectrum antibiotic against anaerobic bacteria, is released from bile after administration and accumulates at high concentrations in the feces, affecting the composition of the intestinal microbiota for a long time, even after discontinuation of dosing.What vitamins should not be taken with clindamycin? ›
Therefore, calcium, iron, magnesium, or zinc supplements, if used, should be taken an hour before or after the drug. Taking calcium, iron, magnesium, or zinc at the same time as minocycline can decrease the absorption of both the drug and the mineral.What is the difference between solution for injection and solution for infusion? ›
The big difference between an infusion and injection is the period of administration. On the one hand, injections are often done within minutes. On the other hand, infusions can take anywhere between 30 minutes to several hours.Is clindamycin available for injection? ›
Clindamycin injection is used to treat bacterial infections in different areas of the body. This medicine is given to patients who had an allergic reaction to penicillin.Is clindamycin an IV or IM? ›
Clindamycin injection should be used undiluted for intramuscular administration.
|To maintain serum clindamycin levels||Rapid infusion rate||Maintenance infusion rate|
|Above 4 mcg/mL||10 mg/min for 30 min||0.75 mg/min|
|Above 5 mcg/mL||15 mg/min for 30 min||1.00 mg/min|
|Above 6 mcg/mL||20 mg/min for 30 min||1.25 mg/min|
(Pharmaceutical: Administration) Infusion, or an infusion, is the introduction of a liquid, such as a saline solution, into a vein or the subcutaneous tissues of the body. Intravenous infusion is used to introduce the solution into the body.What is the difference between an infuse and an injection? ›
Injecting a patient involves a syringe that is carefully held by hands. On the other hand, with an infusion, an IV bag hung up while a tubing and a needle are left in the vein of the patient. The fluid then drips from the bag into the tubing dropwise as set by the nurse or the doctor.What does infuse solution mean? ›
A method of putting fluids, including drugs, into the bloodstream. Also called intravenous infusion.What is the major side effect of clindamycin? ›
Many antibiotics, including clindamycin, may cause overgrowth of dangerous bacteria in the large intestine. This may cause mild diarrhea or may cause a life-threatening condition called colitis (inflammation of the large intestine).
This medication is given by injection into a vein or muscle as directed by your doctor, usually 2 to 4 times a day. The dosage is based on your medical condition and response to treatment.Is clindamycin a first-line antibiotic? ›
Most aerobic Gram-negative bacteria (such as Pseudomonas, Legionella, Haemophilus influenzae and Moraxella) are resistant to clindamycin, as are the facultative anaerobic Enterobacteriaceae. A notable exception is Capnocytophaga canimorsus, for which clindamycin is a first-line drug of choice.Is clindamycin a first-line treatment? ›
First-line agents in managing severe adult streptococcal infection are penicillin 2-4 MU IV every 4-6 hours plus clindamycin 600-900 mg/kg IV every 8 hours.Is clindamycin an expensive drug? ›
|500||$0.40||$198.69 – $199.93|
The cost for clindamycin topical topical gel 1% is around $30 for a supply of 30 grams, depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans. This price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.
- Heart medications like amiodarone (Pacerone) and verapamil.
- Heartburn medications like cimetidine (Tagamet HB)
- Antibiotics like clarithromycin.
- Antifungal medications like itraconazole (Sporanox)
- Antiviral medications like ritonavir (Norvir)